Alto Neuroscience, Inc.

Alto is a clinical-stage biopharmaceutical company focused on developing personalized treatments for psychiatric conditions. The company utilizes its proprietary Precision Psychiatry Platform to identify brain-based biomarkers, aiming to predict which patients will respond to its product candidates. Alto's pipeline includes seven clinical-stage assets targeting major depressive disorder (MDD), bipolar depression (BPD), treatment resistant depression (TRD), schizophrenia, and Parkinson's disease. Its most advanced program is ALTO-207. Founded in 2019, Alto seeks to innovate psychiatry by moving away from a broad approach to central nervous system (CNS) drug development. The company believes its precision approach, which uses neurobiological insights, can lead to more effective treatments for specific patient populations. Alto estimates its portfolio has the potential to impact over 25 million patients in the United States. The Platform uses modern neurobiology measurement tools and data science analytics.